Marco Santonico Selected Research

Volatile Organic Compounds

1/2018	Cluster analysis on breath print of newly diagnosed COPD patients: effects of therapy.
1/2018	Validation of exhaled volatile organic compounds analysis using electronic nose as index of COPD severity.
1/2017	Breath-print analysis by e-nose may refine risk stratification for adverse outcomes in cirrhotic patients.
1/2017	Screening of Obstructive Sleep Apnea Syndrome by Electronic-Nose Analysis of Volatile Organic Compounds.
1/2016	Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study.
11/2015	The lung cancer breath signature: a comparative analysis of exhaled breath and air sampled from inside the lungs.
5/2015	Comorbidity modulates non invasive ventilation-induced changes in breath print of obstructive sleep apnea syndrome patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marco Santonico Research Topics

Disease

6	Lung Neoplasms (Lung Cancer) 05/2024 - 05/2010
4	Chronic Obstructive Pulmonary Disease (COPD) 01/2018 - 01/2012
3	Neoplasms (Cancer) 05/2024 - 05/2012
2	Asthma (Bronchial Asthma) 01/2019 - 04/2010
2	Lung Diseases (Lung Disease) 01/2019 - 01/2017
2	Obstructive Sleep Apnea 01/2017 - 05/2015
2	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2015 - 01/2012
1	Ovarian Neoplasms (Ovarian Cancer) 03/2024
1	Dementia (Dementias) 01/2023
1	Neurodegenerative Diseases (Neurodegenerative Disease) 05/2021
1	Dysbiosis 01/2021
1	Diverticular Diseases 01/2021
1	Heart Failure 09/2020
1	Ascites 01/2020
1	Pleural Effusion (Pleural Effusions) 01/2020
1	Portal Hypertension 01/2020
1	Fibrosis (Cirrhosis) 01/2017
1	Liver Diseases (Liver Disease) 01/2016
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2016
1	Halitosis 03/2008

Drug/Important Bio-Agent (IBA)

7	Volatile Organic CompoundsIBA 01/2018 - 05/2015
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 01/2017
2	GoldIBA 01/2018 - 01/2012
1	AntioxidantsIBA 01/2023
1	diazonaphthalenedisulfonic acid (NDS)IBA 05/2021
1	Rifaximin (L 105)FDA Link 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	AlbuminsIBA 01/2020
1	SteroidsIBA 01/2019
1	SolutionsIBA 05/2012
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2010
1	QuartzIBA 03/2008
1	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 03/2008
1	n-pentanoic acid (valeric acid)IBA 03/2008
1	Butyric Acid (Butanoic Acid)IBA 03/2008

Therapy/Procedure

17	Electronic Nose 05/2024 - 03/2008
3	Therapeutics 01/2021 - 04/2014
1	Continuous Positive Airway Pressure 05/2015
1	Noninvasive Ventilation 05/2015